|
11. |
Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial InfarctionThe Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1316-1323
James Tcheng,
David Kandzari,
Cindy Grines,
David Cox,
Mark Effron,
Eulogio Garcia,
John Griffin,
Giulio Guagliumi,
Thomas Stuckey,
Mark Turco,
Martin Fahy,
Alexandra Lansky,
Roxana Mehran,
Gregg Stone,
Preview
|
PDF (73KB)
|
|
摘要:
Background—Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary percutaneous coronary intervention for acute myocardial infarction (MI) have shown improved early clinical and angiographic outcomes with treatment. However, variations in trial designs, modest sample sizes, and limited long-term follow-up have precluded these studies from being definitive.Methods and Results—As a prespecified secondary analysis of the CADILLAC trial, we compared early and late outcomes by abciximab assignment among 2082 patients randomized in an open-label, 2×2 factorial-design trial of primary stenting versus angioplasty and abciximab treatment (n=1052) versus no abciximab treatment (n=1030). Baseline characteristics were balanced between groups. Abciximab treatment was associated with a significant reduction in the composite end point of death, MI, ischemia-driven target-vessel revascularization (TVR), or disabling stroke at 30 days (4.6% versus 7.0%; relative risk, 0.65; 95% CI, 0.46 to 0.93;P=0.01). Subacute thrombosis also was significantly reduced with abciximab treatment. At 12 months, however, rates of the composite end point did not differ significantly (18.4% for controls versus 16.9% for abciximab-treated patients; relative risk, 0.92; 95% CI, 0.76 to 1.10;P=0.29), reflecting a decrease in the relative difference in TVR rates (ie, no effect of abciximab on reducing restenosis). In an angiographic substudy (n=656), myocardial salvage, restenosis, and infarct-artery reocclusion at 7 months were unaffected by abciximab treatment. There was no significant interaction between stenting and abciximab treatment.Conclusions—Adjunctive abciximab treatment during primary percutaneous coronary intervention significantly enhanced 30-day event-free survival, predominantly by reducing ischemia-driven TVR. Abciximab treatment did not affect the composite end point at 1 year, reflecting a lack of effect on restenosis.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
12. |
Randomized Comparison of Percutaneous Transluminal Coronary Angioplasty and Medical Therapy in Stable Survivors of Acute Myocardial Infarction With Single Vessel DiseaseA Study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1324-1328
Uwe Zeymer,
Rainer Uebis,
Albrecht Vogt,
Hans-Georg Glunz,
Hans-Friedrich Vöhringer,
Dietrich Harmjanz,
Karl-Ludwig Neuhaus,
Preview
|
PDF (73KB)
|
|
摘要:
Background—Percutaneous transluminal coronary angioplasty of the infarct-related artery in stable survivors of acute myocardial infarction is often performed, even in patients without any symptoms or residual ischemia. Despite the lack of randomized studies, it is widely believed that this intervention will improve the clinical outcome of these patients.Methods and Results—Three hundred patients with single vessel disease of the infarct vessel and no or minor angina pectoris in the subacute phase (1 to 6 weeks) after an acute myocardial infarction were randomized to angioplasty (n=149) or medical therapy (n=151). Primary end point was the survival free of reinfarction, (re)intervention, coronary artery bypass surgery, or readmission for severe angina pectoris at 1 year. The event-free survival at 1 year was 82% in the medical group and 90% in the angioplasty group (P=0.06). This difference was mainly driven by the difference in the need for (re)interventions (20 versus 8,P=0.03). At long-term follow-up (mean, 56 months), survival was 89% and 96% (P=0.02). Survival free of reinfarction, (re)intervention, or coronary artery bypass surgery was 66% and 80% in the medically and interventionally treated patients, respectively (P=0.05). The use of nitrates was significantly lower in the angioplasty group, both at 1 year (38% versus 67%,P=0.001) and at long-term follow-up (36% versus 55%,P=0.006).Conclusions—Percutaneous revascularization of the infarct-related coronary artery in stable patients with single vessel disease improves clinical outcome at long-term follow-up and reduces the use of nitrates. The results of our study should be reproduced in a confirmatory study with a larger sample size before percutaneous coronary intervention in this low-risk patient subgroup, after myocardial infarction can be recommended as routine treatment in clinical practice.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
13. |
Percutaneous Pericardial Instrumentation for Endo-Epicardial Mapping of Previously Failed Ablations |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1329-1335
Robert Schweikert,
Walid Saliba,
Gery Tomassoni,
Nassir Marrouche,
Christopher Cole,
Thomas Dresing,
Patrick Tchou,
Dianna Bash,
Salwa Beheiry,
Cathy Lam,
Logan Kanagaratnam,
Andrea Natale,
Preview
|
PDF (360KB)
|
|
摘要:
Background—The epicardial location of an arrhythmia could be responsible for unsuccessful endocardial catheter ablation.Methods and Results—In 48 patients referred after prior unsuccessful endocardial ablation, we considered percutaneous, subxiphoid instrumentation of the pericardial space for mapping and ablation. Thirty patients had ventricular tachycardia (VT), 6 patients had a right- and 4 had a left-sided accessory pathway (AP), 4 patients had inappropriate sinus tachycardia, and 4 patients had atrial arrhythmias. Of the 30 VTs, 24 (6 with ischemic cardiomyopathy, 3 with idiopathic cardiomyopathy, and 15 with normal hearts) appeared to originate from the epicardium. Seventeen (71%) of these 24 VTs were successfully ablated with epicardial lesions. The other 7 VTs had early epicardial sites that were inaccessible, predominantly because of interference from the left atrial appendage. Six of these were successfully ablated from the left coronary cusp. In 5 of the 10 patients with an AP, the earliest activation was recorded epicardially. Three of these were right atrial appendage–to–right ventricle APs, and epicardial ablation was successful. No significant complications were observed.Conclusions—Failure of endocardial ablation could reflect the presence of an epicardial arrhythmia substrate. Epicardial instrumentation and ablation appeared feasible and safe and provided an alternative strategy for the treatment of patients with a variety of arrhythmias. This was particularly true for VT, including patients without structural heart disease.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
14. |
Transcatheter Angioplasty for Acquired Pulmonary Vein Stenosis After Radiofrequency Ablation |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1336-1342
Athar Qureshi,
Lourdes Prieto,
Larry Latson,
Geoffrey Lane,
C. Mesia,
Penelope Radvansky,
Richard White,
Nassir Marrouche,
Eduardo Saad,
Dianna Bash,
Andrea Natale,
John Rhodes,
Preview
|
PDF (187KB)
|
|
摘要:
Background—Pulmonary vein stenosis has recently been recognized as a complication of radiofrequency ablation for atrial fibrillation. This study evaluates the presentation of affected patients and the role of transcatheter therapy for this patient population.Methods and Results—This study used a retrospective review of data from 19 patients (age, 51±13 years) with pulmonary vein stenosis who underwent catheterization and angiography between December 2000 and December 2002. Quantitative perfusion and spiral CT scans were performed for initial diagnosis and follow-up. The median duration between radiofrequency ablation and the reported onset of respiratory symptoms for 18 of 19 patients was 7.5 weeks (0.1 to 48). After the onset of symptoms, all but two patients were initially misdiagnosed with a symptoms-to-diagnosis duration of 16 weeks (2–59). At initial catheterization, 17 of 19 patients had angioplasty in 30 veins with stent placement in 5 vessels when a flap occurred. Overall vessel diameter increased from 2.6±1.6 to 6.6±2.4 mm (P<0.0001). There were 4 procedure-related adverse events but no long-term sequelae. Immediate follow-up showed improved flow to involved lung segments. At a median follow-up of 43 weeks (2–92), although repeat angioplasty for restenosis was necessary in 8 of 17 patients, 15 of 17 patients currently have no or minimal persistent symptoms.Conclusions—Pulmonary vein stenosis after radiofrequency ablation for atrial fibrillation is often misdiagnosed. Although further follow-up is necessary to determine long-term success, our data indicate better pulmonary vein flow and symptomatic improvement in the majority of patients undergoing dilation of postablation pulmonary vein stenosis.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
15. |
Bilateral Versus Unilateral Internal Mammary Revascularization in Patients With Diabetes |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1343-1349
Masahiro Endo,
Yasuko Tomizawa,
Hiroshi Nishida,
Preview
|
PDF (163KB)
|
|
摘要:
Background—This historical cohort study evaluated the benefit of bilateral internal mammary artery (BIMA) grafts in coronary bypass grafting (CABG) for patients with diabetes.Methods and Results—We performed elective, isolated, primary, multiple CABG using skeletonized internal mammary artery (IMA) grafts for multivessel disease in 1131 patients, 467 (41.3%) of whom had type 2 diabetes mellitus. The early and long-term results were compared between 277 patients with diabetes using single IMA (SIMA) grafts and 190 using BIMA grafts (median follow-up, 8.1 years). Hospital mortality was similar in both groups. Early patency rate of all grafts was significantly higher using BIMA than using SIMA (97.7% versus 93.8%,P=0.0012). Survival rates were not significantly different between SIMA and BIMA groups. Late cardiac mortality was significantly higher in patients with low ejection fraction (0.4 or lower) compared with preserved ejection fraction (higher than 0.4) (P=0.0001). In patients with preserved ejection fraction, 10-year survival rate was significantly higher using BIMA than using SIMA (87.8±3.5% versus 75.2±3.4%,P=0.04), and 10-year all death–free or repeat CABG or recurrent myocardial infarction–free rate was significantly higher using BIMA than using SIMA (86.6±3.6% versus 69.0±3.7%,P=0.0086). The hazard ratio for all death or repeated CABG or recurrent myocardial infarction in patients with preserved ejection fraction was markedly lower in the BIMA group (0.53; 95% CI, 0.31 to 0.9;P=0.019).Conclusions—Skeletonized BIMA grafts are beneficial in coronary revascularization for diabetic patients with preserved ejection fraction but have limited survival benefit for those with reduced ejection fraction attributable to high cardiac mortality.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
16. |
Long-Term Results of the Radial Artery Used for Myocardial Revascularization |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1350-1354
Gianfederico Possati,
Mario Gaudino,
Francesco Prati,
Francesco Alessandrini,
Carlo Trani,
Franco Glieca,
Mario Mazzari,
Nicola Luciani,
Giovanni Schiavoni,
Preview
|
PDF (205KB)
|
|
摘要:
Background—No information is available on the long-term results of radial artery (RA) grafts used as coronary artery bypass conduits.Methods and Results—In this report, we describe the long-term (105±9 months) angiographic results of a series of 90 consecutive patients in whom the RA was used as a coronary artery bypass conduit directly anastomosed to the ascending aorta. The long-term patency and perfect patency rates of the RA were 91.6% and 88%, respectively, versus 97.5% and 96.3% for internal thoracic artery grafts. The severity of stenosis of the target vessel clearly influenced long-term RA patency, whereas location of the target vessel and long-term use of calcium channel blockers did not influence angiographic results. Preserved endothelial function and absence of flow-limiting, fibrous, intimal hyperplasia were also documented.Conclusions—Ten years after surgery, RA grafts have excellent patency and perfect patency rates. Appropriate surgical technique and correct indication are the key factors for long-term RA patency.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
17. |
Rapid Left-to-Right Shunt Quantification in Children by Phase-Contrast Magnetic Resonance Imaging Combined With Sensitivity Encoding |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1355-1361
Philipp Beerbaum,
Hermann Körperich,
Jürgen Gieseke,
Peter Barth,
Matthias Peuster,
Hans Meyer,
Preview
|
PDF (114KB)
|
|
摘要:
Background—Parallel imaging by sensitivity encoding (SENSE) may considerably reduce scan time in MRI. For rapid flow quantification in children with congenital heart disease, we evaluated phase-contrast MRI (PC-MRI) techniques combined with SENSE.Methods and Results—In 22 pediatric patients (mean age, 7.2±6.2 years) with cardiac left-to-right shunt, blood flow rate in the pulmonary artery (Qp) and ascending aorta (Qs) and flow ratio Qp/Qswere determined by PC-MRI with SENSE reduction-factor 2 and 3 (SF-2 and SF-3). Additionally, we used PC-MRI with higher spatial in-plane resolution (1.6×2.1 versus 2.3×3.1 mm) with and without SF-3. Results were compared with a recently validated standard PC-MRI protocol and tested in vitro using a pulsatile flow phantom. Reduction of signal averages from 2 to 1 and application of SENSE accelerated flow measurements by a factor of 3.5 (5.2) using PC-MRI with SF-2 (SF-3) compared with standard PC-MRI. For blood flow rate through the pulmonary artery and aorta, as well as for the Qp/Qsratio we found negligible differences of ±3%, lower limits of agreement (mean±2 SD) of −7% to −18%, and upper limits of agreement (mean±2 SD) of +3 to +24%, demonstrating good agreement with standard PC-MRI. Mean Qp/Qsratio by standard PC-MRI was 1.69±0.45 (range, 1.27 to 2.79). Interobserver variability was low, and high accuracy was confirmed in vitro for all protocols.Conclusions—PC-MRI for flow quantitation may be combined with SENSE to achieve a substantive reduction of scanning time. In children with left-to-right shunt, Qp/Qsquantification is possible by PC-MRI+SF-3 in <60 seconds. Use of higher in-plane resolution did not improve measurement results.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
18. |
Cerebral Venous Thrombosis in ChildrenA Multifactorial Origin |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1362-1367
Christine Heller,
Achim Heinecke,
Ralf Junker,
Ralf Knöfler,
Andrea Kosch,
Karin Kurnik,
Rosemarie Schobess,
Arnold von Eckardstein,
Ronald Sträter,
Barbara Zieger,
Ulrike Nowak-Göttl,
Preview
|
PDF (48KB)
|
|
摘要:
Background—The present study was performed to assess the association of prothrombotic risk factors and underlying conditions (infections, vascular trauma, immobilization, malignancies, autoimmune diseases, renal diseases, metabolic disorders, obesity, birth asphyxia, cardiac malformations, and use of prothrombotic drugs) with cerebral venous thrombosis (CVT) in children.Methods and Results—From 1995 to 2002, 149 pediatric patients aged newborn to <18 years (median 6 years) with CVT were consecutively enrolled. In patients and in 149 age- and gender-matched children with similar underlying clinical conditions but without CVT, the factor V G1691A mutation, the factor II G20210A variant, lipoprotein(a) [Lp(a)], protein C, protein S, antithrombin, and antiphospholipid antibodies, as well as associated clinical conditions, were investigated. Eighty-four (56.4%) of the patients had at least 1 prothrombotic risk factor compared with 31 control children (20.8%;P<0.0001). In addition, 105 (70.5%) of 149 patients with CVT presented with an underlying predisposing condition. On univariate analysis, factor V, protein C, protein S, and elevated Lp(a) were found to be significantly associated with CVT. However, in multivariate analysis, only the combination of a prothrombotic risk factor with an underlying condition (OR 3.9, 95% CI 1.8 to 8.6), increased Lp(a) (OR 4.1, 95% CI 2.0 to 8.7), and protein C deficiency (OR 11.1, 95% CI 1.2 to 104.4) had independent associations with CVT in the children investigated.Conclusions—CVT in children is a multifactorial disease that, in the majority of cases, results from a combination of prothrombotic risk factors and/or underlying clinical condition.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
19. |
Rosuvastatin Reduces Atherosclerosis Development Beyond and Independent of Its Plasma Cholesterol–Lowering Effect in APOE*3-Leiden Transgenic MiceEvidence for Antiinflammatory Effects of Rosuvastatin |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1368-1374
Robert Kleemann,
Hans Princen,
Jef Emeis,
J. Jukema,
Ruud Fontijn,
Anton Horrevoets,
Teake Kooistra,
Louis Havekes,
Preview
|
PDF (456KB)
|
|
摘要:
Background—Statins can exert anti-inflammatory antiatherosclerotic effects through an anti-inflammatory action, independent of lowering cholesterol. We addressed the question whether the anti-inflammatory activities of statins can reduce atherosclerosis beyond the reduction achieved by cholesterol lowering per se.Methods and Results—Two groups of 20 female APOE*3-Leiden mice received either a high-cholesterol diet (HC) or a high-cholesterol diet supplemented with 0.005% (wt/wt) rosuvastatin (HC+R). The HC diet alone resulted in a plasma cholesterol concentration of 18.9±1.4 mmol/L, and administration of rosuvastatin lowered plasma cholesterol to 14.1±0.7 mmol/L. In a separate low-cholesterol (LC) control group, the dietary cholesterol intake was reduced, which resulted in plasma cholesterol levels that were comparable to the HC+R group (13.4±0.8 mmol/L). Atherosclerosis in the aortic root area was quantified after 24 weeks. As compared with the HC group, the LC group had a 62% (P<0.001) reduction in cross-sectional lesion area. When compared with the LC group, the HC+R group showed a further decrease in cross-sectional lesion area (80%,P<0.001), size of individual lesions (63%,P<0.05), lesion number (58%,P<0.001), monocyte adherence (24%,P<0.05), and macrophage-containing area (60%,P<0.001). Furthermore, rosuvastatin specifically suppressed the expression of the inflammation parameters MCP-1 and TNF-&agr; in the vessel wall and lowered plasma concentrations of serum amyloid A and fibrinogen, independent of its cholesterol-lowering effect.Conclusions—Rosuvastatin reduces atherosclerosis beyond and independent of the reduction achieved by cholesterol lowering alone. This additional beneficial effect of rosuvastatin may be explained, at least partly, by its anti-inflammatory activity.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
20. |
Deficiency of Gelatinase A Suppresses Smooth Muscle Cell Invasion and Development of Experimental Intimal Hyperplasia |
|
Circulation: Journal of the American Heart Association,
Volume 108,
Issue 11,
2003,
Page 1375-1381
Masafumi Kuzuya,
Shigeru Kanda,
Takeshi Sasaki,
Norika Tamaya-Mori,
Xian Cheng,
Takeshi Itoh,
Shigeyoshi Itohara,
Akihisa Iguchi,
Preview
|
PDF (349KB)
|
|
摘要:
Background—Although it has been demonstrated that matrix metalloproteinases (MMPs) play an important role in the arterial remodeling in atherosclerosis and restenosis, it is not clear which MMP is involved in which process. To define the role of MMP-2 in arterial remodeling, we evaluated the influence of the targeted deletion of the MMP-2 gene on vascular remodeling after flow cessation in the murine carotid arteries.Methods and Results—The left common carotid arteries of wild-type and MMP-2–deficient mice were ligated just proximal to their bifurcations, and the animals were then processed for morphological and biochemical studies at specific time points. MMP-2 activity and mRNA levels increased in ligated carotid arteries of wild-type mice on the basis of observation by gelatin zymography and quantitative real-time RT-PCR. There was significantly less intimal hyperplasia in MMP-2–deficient mice at 2 and 4 weeks after ligation than there in wild-type mice. Arterial explants from the aorta of MMP-2–deficient mice showed that smooth muscle cell (SMC) migration was inhibited in comparison with wild-type mice. The chemoattractant-directed invasion through a reconstituted basement membrane barrier was significantly reduced in cultured SMCs derived from MMP-2–deficient mice, although no difference was observed in SMC migration across the filter or in proliferative response between the control and MMP-2–deficient mice.Conclusions—In a mouse carotid artery blood flow cessation model, MMP-2 contributes to intimal hyperplasia mainly through the SMC migration from the media into the intima by degrading and breaching the extracellular matrix proteins surrounding each cell and the internal elastic lamina.
ISSN:0009-7322
出版商:OVID
年代:2003
数据来源: OVID
|
|